Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients

Area of Science:

• Cardiovascular Surgery
• Interventional Cardiology
• Pediatric Cardiology

Background:

• Reconstruction of the right ventricular outflow tract (RVOT) in children using valved conduits often necessitates reintervention due to pulmonary regurgitation and stenosis.
• Congenital heart disease repair in infancy and childhood can lead to long-term complications such as pulmonary regurgitation and stenosis.

Purpose of the Study:

• To evaluate the feasibility and outcomes of percutaneous pulmonary valve implantation (PPVI) in patients with pulmonary regurgitation and/or stenosis post-congenital heart disease repair.
• To assess hemodynamic improvement, freedom from explantation, and changes in exercise tolerance following PPVI.

Main Methods:

• PPVI was performed in 58 patients (median age 16 years) with pulmonary regurgitation and/or stenosis.
• Key endpoints included mortality, hemodynamic parameters, explantation rates, and exercise capacity.
• Cardiac MRI and metabolic exercise testing were utilized to assess ventricular function and exercise tolerance.

Main Results:

• PPVI was successfully performed in all 58 patients with no mortality.
• Significant reductions were observed in right ventricular pressure, RVOT gradient, and pulmonary regurgitation.
• Cardiac MRI demonstrated significant improvements in pulmonary regurgitation fraction, RV end-diastolic volume, and left ventricular end-diastolic volume, alongside increased effective RV stroke volume.
• Metabolic exercise testing showed a significant improvement in VO2max in a subset of patients.

Conclusions:

• PPVI is a feasible and low-risk intervention for managing pulmonary regurgitation and stenosis after RVOT reconstruction.
• The procedure leads to quantifiable improvements in cardiac MRI-defined parameters and pulmonary regurgitation.
• PPVI results in both subjective and objective enhancements in patient exercise capacity.